SecBot SecBot
8-K ·Filed Apr 6, 2026

SLNO

SOLENO THERAPEUTICS INC
BULLISH
Impact 8/10
Horizonmonths Processed7mo ago SEC0001193125-26-142911
8-K material event: Items 1.01
Actionable Insight ▲ Bullish

The acquisition significantly strengthens Neurocrine's portfolio in endocrinology and rare diseases with a first-in-class therapy that has demonstrated strong commercial traction. The $92 million in Q4 2025 revenue suggests accelerating adoption of VYKATTM XR, which could drive substantial revenue growth post-acquisition. Traders should monitor integration progress and potential synergies, as well as any regulatory developments that could impact the expected 90-day closing timeline.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$52.25
T+0 close · Apr 6, 2026 · via day close
Latest settled
+1.24%
T+20 · $52.90
Vs SPY
−7.74%
α at T+20
Next horizon
T+60
due 5mo ago
  1. T+0 · Apr 6 $52.25entry
  2. T+1 · 7mo ago +0.19%α +0.13% · $52.35
  3. T+5 · 7mo ago +0.75%α −3.39% · $52.64
  4. T+20 · 7mo ago +1.24%α −7.74% · $52.90
  5. T+60 · due 5mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Neurocrine Biosciences will acquire Soleno Therapeutics for $53.00 per share in cash, representing a total equity value of $2.9 billion. The acquisition includes Soleno's FDA-approved treatment VYKATTM XR for Prader-Willi syndrome, which generated $190 million in 2025 revenue. The deal is expected to close within 90 days, subject to regulatory approvals and other customary conditions.

Key Financial Metrics

Deal Value
$2.9B
Premium
34%
Deal Type
acquisition

Key Facts

  • Neurocrine Biosciences will acquire Soleno Therapeutics for $53.00 per share in cash
  • Total transaction equity value is $2.9 billion
  • VYKATTM XR generated $190 million in 2025 revenue, including $92 million in Q4 2025
  • The deal represents a 34% premium to Soleno's closing price on April 2, 2026
  • The acquisition is expected to close within 90 days of announcement
  • The transaction is funded with cash on hand and modest pre-payable debt

Financial Impact

Total equity value of $2.9 billion with $53.00 per share cash payment

market capitalizationrevenuecash flowdilution

Risk Factors

  • Regulatory approval delays
  • Integration challenges between the two companies
  • Potential competition from alternative treatments for Prader-Willi syndrome

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-142911
Document: d142985dex101.htm0001193125-26-142911
Document: d142985d8k.htm0001193125-26-142911
Document: d142985dex991.htm0001193125-26-142911
Document: 0001193125-26-142911-index-headers.html0001193125-26-142911
Document: 0001193125-26-142911-index.html0001193125-26-142911
Document: 0001193125-26-142911.txt0001193125-26-142911

Track record

10 reports on SLNO

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Jun 11, 202622w ago Institutional Cluster Bullish 6/10 No price data
  2. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 No price data
  3. May 28, 202624w ago 15-12G Bearish 8/10 No price data
  4. May 28, 202624w ago EFFECT Bearish 5/10 No price data
  5. May 18, 202626w ago 8-K / 25-NSE Bullish 8/10 Entry $53.01 No price data
  6. Apr 7, 202631w ago 8-K Bearish 7/10 Entry $52.35 to $52.62 ▼ −0.52% +4.81% vs SPY
  7. Apr 6, 202632w ago 8-K Bullish 8/10 Viewing Entry $52.25 to $52.64 ▲ +0.75% −3.39% vs SPY
  8. Mar 27, 202633w ago Insider Cluster Neutral 3/10 Entry $30.05 to $52.25 ▲ +73.88% +70.01% vs SPY
  9. Feb 26, 202637w ago 8-K Bullish 8/10 Entry $38.09 to $38.57 ▲ +1.26% +2.42% vs SPY
  10. Feb 26, 202637w ago 8-K Neutral 3/10 Entry $38.09 to $38.57 ▲ +1.26% +2.39% vs SPY
Showing 10 of 10

US Market Status

Market Closed · Opens in 7h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 6, 2026